#Acute Pain Drug Pipeline Analysis share | Explore Tumblr posts and blogs

exp-market-research111 · 10 days ago

Text

Acute Pain Drug Pipeline Analysis Report 2024

According to the National Institutes of Health’s National Center for Complementary and Integrative Health (NCCIH), approximately 40 million adults (17.6%) experience severe levels of pain in the United States. The treatment for acute pain includes a combination of drugs and therapies. Common medications involve anti-seizure drugs, shots, muscle relaxers, and opioids. Several clinical trials are actively developing effective treatments, including advanced analgesics. Recently, the FDA granted VX-548 Breakthrough Therapy Designation for the treatment of moderate to severe acute pain, highlighting significant progress in addressing this widespread issue.

Acute pain, typically short-term, arises from injury, surgery, or other immediate conditions and can significantly impact a patient’s quality of life. With growing concerns over opioid dependency, the drug pipeline is shifting toward innovative therapies that provide effective relief without the risks associated with traditional treatments.

Acute Pain Drug Pipeline Analysis Overview

The acute pain drug pipeline focuses on developing non-addictive, effective, and safer alternatives to opioids while addressing various pain mechanisms. The analysis reveals the following key aspects:

Non-Opioid Analgesics: A primary focus is on non-opioid drugs that target pain at the molecular level, such as nerve blockers and receptor inhibitors.

Combination Therapies: Drugs combining analgesics with anti-inflammatory agents are showing promise in clinical trials.

Phases of Development: Most drugs in the pipeline are in phases II and III of clinical trials, with several candidates expected to enter the market in the next 5-7 years.

Innovations in the Pipeline:

Voltage-Gated Sodium Channel Inhibitors: Drugs like VX-548 aim to block pain signals at the source.

Capsaicin-Based Drugs: Leveraging natural compounds for targeted pain relief.

Cannabinoid-Based Therapies: Investigating the role of cannabis-derived compounds in managing acute pain.

Acute Pain Drug Pipeline Analysis Dynamics

The acute pain drug pipeline is influenced by several factors that drive growth and innovation, as well as challenges that slow progress.

Market Drivers:

High Prevalence of Acute Pain: Increasing cases due to surgeries, injuries, and chronic conditions transitioning to acute episodes.

Demand for Non-Addictive Alternatives: Rising awareness of the opioid crisis has spurred the search for safer options.

Technological Advancements: Use of AI and machine learning in drug discovery accelerates pipeline progression.

Market Restraints:

Regulatory Hurdles: Stricter guidelines on clinical trials and approvals delay market entry.

Cost of Development: High R&D costs for novel therapies are a significant challenge.

Opportunities:

Personalized Medicine: Tailoring treatments based on genetic and molecular profiling.

Emerging Markets: Expanding healthcare infrastructure in Asia-Pacific and Latin America offers growth potential.

External Acute Pain Drug Pipeline Analysis Trends

External factors influencing the pipeline include patient demand for effective treatments, technological breakthroughs, and evolving healthcare policies.

Get a Free Sample Report with Table of Contents https://www.expertmarketresearch.com/clinical-trials/acute-pain-drug-pipeline-insight/requestsample

Current Trends:

Digital Health Integration: Pain management apps are aiding in tracking pain levels and treatment efficacy.

Wearable Drug Delivery Systems: Devices providing localized drug delivery are gaining traction.

Biologics in Pain Management: Use of antibodies and other biologics to target pain pathways precisely.

Acute Pain Drug Pipeline Analysis Segmentation

The acute pain drug market can be segmented by drug class, route of administration, and geography.

By Drug Class:

NSAIDs: Non-steroidal anti-inflammatory drugs remain the most prescribed for acute pain.

Opioids: Still used for severe cases, though usage is declining due to addiction risks.

Non-Opioid Alternatives: Growing focus on drugs like capsaicin creams and cannabinoids.

Others: Anti-seizure medications and muscle relaxers.

By Route of Administration:

Oral: Preferred for ease of use and patient compliance.

Injectable: For rapid relief in severe pain episodes.

Topical: Emerging as a popular option for localized pain management.

By Geography:

North America: Largest market share due to advanced healthcare systems and high prevalence.

Europe: Strong focus on reducing opioid dependency drives innovation.

Asia-Pacific: Fastest-growing region with increasing healthcare access.

Acute Pain Drug Pipeline Analysis Growth

The acute pain drug pipeline is poised for robust growth, driven by innovation and a shift toward safer alternatives.

Growth Factors:

Increased Funding: Governments and private players are heavily investing in pain management research.

Regulatory Incentives: Orphan drug designations and expedited approvals for promising drugs.

Awareness Campaigns: Initiatives to educate patients and providers about non-opioid options.

Growth Projections:

The global acute pain drug market is expected to grow at a CAGR of 7.5% from 2024 to 2032, with significant contributions from non-opioid therapies.

Recent Developments in the Virus Filtration Market

The virus filtration market plays a critical role in ensuring the safety of biologics and advanced therapies used in acute pain management.

Key Developments:

Advanced Filtration Technologies: Nanofiltration ensures better virus removal from biologic drugs.

Regulatory Updates: Stricter compliance requirements improve drug safety and efficacy.

Automation in Filtration: Increased use of automated systems reduces contamination risks.

Acute Pain Drug Pipeline Analysis Scope

The scope of acute pain drug pipeline analysis encompasses a wide range of innovative treatments and market strategies aimed at improving patient outcomes.

Key Areas of Focus:

Non-Addictive Pain Relievers: Development of safer, long-term solutions.

Targeted Delivery Systems: Ensuring precision in drug administration.

Global Access: Making therapies affordable and available worldwide.

Acute Pain Drug Pipeline Analysis

The analysis reveals the following insights into the acute pain drug pipeline:

Clinical Trials: A significant number of drugs are in advanced stages of development.

Unmet Needs: Opportunities exist in targeting under-addressed pain mechanisms.

Market Competition: Players like Centrexion Therapeutics and Aponia Laboratories are at the forefront of innovation.

COVID-19 Impact Analysis

The COVID-19 pandemic had a mixed impact on the acute pain drug pipeline:

Delays: Clinical trials were postponed due to restrictions.

Acceleration: Virtual trials and AI-driven drug discovery gained momentum.

Increased Demand: Post-COVID complications led to a surge in acute pain cases.

Key Players in the Acute Pain Drug Pipeline

1. Centrexion Therapeutics

Focused on non-opioid pain relievers such as CNTX-4975, targeting severe localized pain.

2. Alaxia SAS

Developing innovative therapies for pain management through oxidative stress modulation.

3. Purdue Pharma, Canada

Known for its expertise in pain management, focusing on non-opioid solutions.

4. Aponia Laboratories, Inc.

Innovating in the development of combination therapies and extended-release formulations.

FAQ

What is acute pain?

Acute pain is short-term pain that occurs due to injury, surgery, or illness and typically resolves once the underlying cause is treated.

How is acute pain treated?

Common treatments include NSAIDs, opioids (for severe cases), muscle relaxers, and non-pharmacological approaches like physical therapy.

What are the risks of opioid use for acute pain?

Opioids carry a risk of addiction, dependency, and side effects, leading to a growing focus on non-opioid alternatives.

What are some emerging therapies in acute pain management?

Emerging therapies include voltage-gated sodium channel inhibitors, cannabinoid-based drugs, and biologics targeting pain pathways.

How has COVID-19 impacted acute pain management?

COVID-19 disrupted clinical trials but also accelerated innovation in virtual trials and remote monitoring tools.

#Acute Pain Drug Pipeline Analysis forecast #Acute Pain Drug Pipeline Analysis share

0 notes

pharmanucleus1 · 7 months ago

Text

Chronic Bronchitis Market: Advancements in Respiratory Care

Chronic Bronchitis Market Analysis and Size

The global chronic bronchitis market is expected to grow considerably over the projected period. The global increase in allergic reactions, as well as the growth of emerging markets, are moving this industry ahead. The increased prevalence of asthma and COPD, both of which cause severe coughing, is driving the chronic bronchitis market. The market is growing and is expected to grow fast throughout the projected period.

Click here for full report:

Pharmanucleus investigates the growth rate of the global chronic bronchitis market from 2023 to 2030. During the projected period, the worldwide chronic bronchitis market is estimated to grow at a CAGR of more than 4.0%. The Pharmanucleus team performed a thorough market analysis that included expert research, patient epidemiology, pipeline analysis, price analysis, and regulatory framework, as well as market data such as market size, growth rate, market segmentation, geographical coverage, market participants, and market situation.

Market Definition

Chronic bronchitis is an inflammatory disease that produces swelling and pain in the airways over time. The symptoms appear gradually and build to severe, maybe irreversible lung damage. A three-month cough happens every two years. The most common causes of chronic bronchitis include smoking and certain kinds of chronic obstructive pulmonary disease (COPD).

Global Acute Bronchitis Market Dynamics

Drivers

Increasing Prevalence of COPD

The rising incidence of COPD is a significant factor driving market expansion. According to a WHO report from June 2021, chronic obstructive pulmonary disease (COPD) is the third greatest cause of mortality globally, accounting for 3.23 million deaths in 2019. As a result, the rising prevalence of COPD is boosting need for chronic bronchitis therapy.

Growing Demand for Combination Therapy

Combination treatment is becoming increasingly popular since it is more effective than taking a bronchodilator and a corticosteroid individually. The growing number of patients effectively treated with combination therapy who did not respond to bronchodilators or corticosteroids is predicted to fuel the worldwide chronic obstructive pulmonary disease treatment market.

Click here for full report:

Opportunities

Rising Prevalence of Smoking

Smoking is one of the leading causes of death in the United States, resulting in more than 480,000 deaths each year. Smoking was highest among people aged 25-44 and 45-64. Thus, in turn, this leads to chronic bronchitis and creates opportunities for market growth.

Advanced Clinical Research and Innovative Strategies

Many industry participants are eager to put in place strategic measures that will help the sector thrive. The US Food and Drug Administration authorised Brovana in February 2022 for the treatment of bronchoconstriction in persons with chronic obstructive pulmonary disease (COPD). Brovana contains a bronchodilator, which is a medication that relaxes and widens the airways, hence relieving bronchoconstriction.

Restraints/Challenges

Lack of Awareness

Lack of patient awareness about the disease and differentiated symptoms could curb the growth of the global acute bronchitis market over a forecast period.

High Cost

The huge expenditure required for chronic bronchitis treatment is surely hampering the growth of the market.

This Global Chronic Bronchitis Market report provides details about recent new developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share , the impact of national and localized market players, analyzes opportunities in terms of emerging revenue pockets, changes in market regulations, strategic analysis of market growth, market size, category market growth, niches and application dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To obtain more insights on the Global Chronic Bronchitis Market, contact Pharmanucleus for an Analyst Brief, our team will help you make an informed market decision to achieve market growth.

Click here for request free sample report:

Chronic Bronchitis Market Scope

The global chronic bronchitis market is classified into four segments: treatment type, drug class, administration technique, end user, and distribution channel. Growth in these sectors will help you analyse weak growth areas in industries and provide users with important market knowledge and industry insights to help them make strategic decisions to uncover major market applications.

Treatment Type

Pharmacological

Nonpharmacological

Others

Drug Class

Bronchodilators

Glucocorticoids

Antibiotic

Phosphodiesterase-4 Inhibitors

Others

Route of Administration

Oral

Parenteral Inhalational

Others

End-Users

Hospitals

Specialty Clinics

Others

Distribution Channel

Hospitals

Specialty Clinics

Others

Regional Analysis/Insights

The global chronic bronchitis market is analyzed and market size insights and trends are provided by treatment type, drug class, route of administration, end user, and distribution channel as listed above.

The major countries covered in the global Chronic Bronchitis market report are USA, Canada & Mexico North America, Germany, France, UK, Netherlands, Switzerland , Belgium, Russia, Italy, Spain, Turkey, the rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia Pacific (APAC) within Asia Pacific (APAC), Saudi Arabia, United Arab Emirates, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) within Middle -East and Africa (MEA), Brazil, Argentina and rest of South America as part of South America.

North America holds the largest market share owing to increasing infections in the geriatric population and growing smoking population.

Because of the rising incidence of COPD, asthma, and other lung disorders, as well as enhanced government and pharmaceutical organisation efforts to raise awareness, Asia-Pacific is likely to account for the greatest market share in the Chronic Bronchitis market in the next years.

The nation portion of the research also includes individual market affecting elements and changes in legislation in the market that affect present and future market trends. Additionally, the presence and availability of global brands, as well as the issues they face owing to big or scarce competition from local and domestic brands, are taken into account when giving forecast analysis of nation data.

#chronic bronchitis #respiratory care #lung health advancements #bronchitis treatments #pulmonary condition management

0 notes

clevertimetravelpaper · 2 years ago

Text

Anti-Inflammatory Therapeutics Market by Size, Demand, Development, Opportunity, Growth, Trends and Forecast

Global anti-inflammatory therapeutics market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing with the healthy CAGR in the above-mentioned research forecast period. Emerging markets and huge investment in research and development are the factors responsible for the growth of this market.

The growth of anti-inflammatory therapeutics market is anticipated by the high prevalence of chronic disorders such as arthritis and psoriasis and rise in focuses on the anti-inflammatory therapeutics. In addition, increase patient awareness level, availability of the treatment options and adoption of sedentary life-style are some of the influencing factors for the growth of anti-inflammatory therapeutics market. The market for anti-inflammatory therapeutics is majorly hampered by limited revenue opportunities with multiple patent expiries of branded drugs. Anti-inflammatory drugs are therapeutics which is widely used to reduce acute as well as mild chronic pain associated with the chronic disorders. It is available as over-the counter and prescription drugs. Basically, these drugs inhibit the production of certain body chemicals that cause inflammation.

Get a Sample PDF of the report – https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-anti-inflammatory-therapeutics-market

This anti-inflammatory therapeutics market report provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographical expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Anti-Inflammatory Therapeutics Market Scope and Market Size

Anti-inflammatory therapeutics market is segmented on the basis of drug class, indications, end-users and distribution channel.

Based on drug class, the anti-inflammatory therapeutics market is segmented into anti-inflammatory biologics, corticosteroids, nonsteroidal anti-inflammatory (NSAID) and others

Indications segment for anti-inflammatory therapeutics market is categorized into arthritis, respiratory diseases, multiple sclerosis, psoriasis, inflammatory bowel disease and others

On the basis of end-users, the anti-inflammatory therapeutics market is segmented into hospitals, homecare, specialty clinics and others

On the basis of distribution channel, the anti-inflammatory therapeutics market has been bifurcated into hospital pharmacy, online pharmacy and retail pharmacy

To Gain More Insights into the Market Analysis, Browse Summary of the Research Report@- https://www.databridgemarketresearch.com/reports/global-anti-inflammatory-therapeutics-market

Global Anti-Inflammatory Therapeutics Market Country Level Analysis

Anti-inflammatory therapeutics market is analysed and market size information is provided by country, drug class, indications, end-users and distribution channel as referenced above. The countries covered in the global anti-inflammatory therapeutics market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific. Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

Based on geography, North America holds the largest market share for anti-inflammatory therapeutics owing to the high prevalence of psoriasis and irritable bowel and large availability of treatment options. Europe is considered to be second growing regional segment due to the increases focuses on the research and development activity by regional key players. Asia-Pacific leads the market for anti-inflammatory therapeutics due to the presence of key generic pharmaceuticals companies in this region.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Global Anti-Inflammatory Therapeutics Market Share Analysis

Anti-inflammatory therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to global anti-inflammatory therapeutics market.

The major players covered in the anti-inflammatory therapeutics market are GlaxoSmithKline plc, Johnson & Johnson Services, Inc, Glenmark Pharmaceuticals Inc, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Tolmar Pharmaceuticals, Inc, Amneal Pharmaceuticals LLC, Aurobindo Pharma, Merro Pharmaceutical Co.,Ltd, Dr. Reddy’s Laboratories Ltd among others.

Browse the complete table of contents at-

Top Healthcare Reports:

Allogenic Stem Cell Therapy Market Size, Shares, Trends and Industry Growth Outlook https://www.databridgemarketresearch.com/reports/global-allogenic-stem-cell-therapy-market

Cancer Stem Cell Therapy Market – Size, Shares, Trends and Industry Growth Outlook https://www.databridgemarketresearch.com/reports/global-cancer-stem-cell-therapy-market

North America Stem Cell Therapy Market – Size, Shares, Trends and Industry Growth Outlook https://www.databridgemarketresearch.com/reports/north-america-stem-cell-therapy-market

Europe Stem Cell Therapy Market – Size, Shares, Trends and Industry Growth Outlook https://www.databridgemarketresearch.com/reports/europe-stem-cell-therapy-market

Asia-Pacific Stem Cell Therapy Market – Size, Shares, Trends and Industry Growth Outlook https://www.databridgemarketresearch.com/reports/asia-pacific-stem-cell-therapy-market

Middle East and Africa Stem Cell Therapy Market – Size, Shares, Trends and Industry Growth Outlook https://www.databridgemarketresearch.com/reports/middle-east-and-africa-stem-cell-therapy-market

Asia-Pacific Drug-Device Combination Market – Size, Shares, Trends and Industry Growth Outlook https://www.databridgemarketresearch.com/reports/global-drug-device-combination-market

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today! Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:-

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:- [email protected]

0 notes

jayu123-me · 3 years ago

Text

Agmatine Market Opportunities to Watch Through the COVID-19 Pandemic & Beyond

Agmatine Market: Overview

Research and development spending by industries in the agmatine market has spiraled on the axis of the healthcare pursuit of finding safer and effacious neuroprotective agents. Considered as an endogenous ligand of imidazoline and α2-adrenergic receptors, agmatine has surged in popularity on the back of the clinical potential of agmatinergic system. Researchers keen on harnessing the potential of agmatine-mediated effects have been encouraged by the striking worldwide morbidity of neurological diseases.

Driven by the mounting urge to discover drug agents for range of neurological diseases, from acute attack to chronic neurodegenerative ones, agmatine has been comprehensively studied. Specifically, the factor flaring interest is the role of agmatine-mediated products in mechanisms of anti-apoptosis and anti-inflammation. Areas such as brain blood barrier (BBB) protection and brain edema prevention have attracted an intense pharmaceutical industry interest.

On the other end of the spectrum, businesses expanding to supplement industry eye a large potential in the agmatine market. Agmatine-mediated agents might help fight neuropathic pain and drug addiction, as some preliminary studies claimed. All these help attract industry players of different hues.

Request for Covid-19 Impact Analysis :

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=79733

Agmatine Market: Key Trends

Over the past couple decades, the glaring morbidity of neurological diseases has spurred research in their etiology and mechanism. Strokes, particularly ischemic Strokes have been particularly, have been subject to widespread studies, and the role of agmatine has spiraled beyond the lab setting to industry setting. Of note, neuroprotective effects of agmatine both in vivo and in vitro have pooled in investments. The mortality of strokes in adults is a key factor intensifying such studies in the agmatine market.

Buy Now :

https://www.transparencymarketresearch.com/checkout.php?rep_id=79733&ltype=S

There seems to be a marked absence of ideal therapeutic drugs in the drug pipeline for treating patients with traumatic brain injury (TBI). The rising incidence of TBI has also nudged researchers to scrutinize the effects of agmatine in a bid to fill this gap.

Another area that is likely to add remunerative prospects to players in the agmatine market is the Alzheimer’s disease. Being the most common neurodegenerative diseases, the Alzheimer’s is attracting research on opening new avenues in agmatine market. Rise in spending on the healthcare has also brought supplement to the forefront. This has lent momentum to expanding overall avenue in the agmatine market.

Get Brochure of the Report @

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=79733

Agmatine Market: Competitive Analysis and Key Developments

The study takes a closer look at the key growth dynamics, recent research and future directions, and trends in investments that will open up new possibilities in the agmatine market. It also tracks the strategies that emerging and established players have pinned hopes on to target new applications.

New channels of investments in neurological diseases research has attracted several players to test water in the agmatine market. Numerous industry players hope to gain from the rise in research on neuroprotective agents and taking an active part in this. Top players are also getting into partnerships to leverage the synergistic capability.

This has also motivated agmatine manufacturers and suppliers, and others in the value chain to work collaboratively. This include manufacturers of supplements. Over the recent years, the entry of new players has sought to raise the ante higher for incumbent players. Emerging players are increasingly aiming at product differential to consolidate their shares in the agmatine market.

More Trending Reports by Transparency Market Research –

https://www.prnewswire.co.uk/news-releases/acetylglucosamine-market-to-advance-at-cagr-of-7-3-during-forecast-period-widespread-application-in-dietary-supplements-to-generate-substantial-revenue-streams-tmr-study-886444689.html

Agmatine Market: Regional Assessment

Marked proclivity among consumers for supplements in North America and Europe for their health benefits have made them highly lucrative markets. These regional agmatine markets have also gained product development avenues on the back of the spate of studies on testing neuroprotective effects of agmatine on neurological diseases. Countries such as China, India, Mexico, and Nigeria are seeing rise in potential due to the growing awareness about the morbidity of neurological diseases.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers’ or customers’ journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

About Us:

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyse information. Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the unified market intelligence engine. Sign Up for a 7 day free trial!

Contact

Rohit Bhisey Transparency Market Research, 90 State Street, Suite 700, Albany, NY 12207 Tel: +1-518-618-1030 USA – Canada Toll Free: 866-552-3453 Email: [email protected] Website: https://www.transparencymarketresearch.com

0 notes

marketreports-world · 3 years ago

Text

Global Migraine Drugs Market 2021 Size, Status and Forecast to 2027

Global Migraine Drugs Market Research Report: By Type (Episodic Migraine, Chronic Migraine), By Treatment Type (Acute, Preventive, Neuromodulation Devices), By Drug Class (Triptans, Betablockers, Angiotensin Blockers, Tricyclics, Anticonvulsants) and By End-User (Hospitals and Clinics, Retail Pharmacy, Online Pharmacy, Others) – Forecast to 2027

Market Highlights

According to MRFR analysis, the global migraine drugs market is expected to register a CAGR of 5.9% during the forecast period of 2019 to 2025 and was valued at USD 4.4 billion in 2018.

Migraine is a common neurovascular sickness that is characterized by tender headaches and is commonly associated with other neurological indications, such as nausea, vomiting, and painful sensitivity to lights and sounds. Migraine is more common in women than men, majorly due to the fluctuations in the hormone levels. Approximately 12% of the US population suffered from migraine headaches in 2018. The treatment of migraine headaches is eased by the administration of preventive medications, to avoid migraine attacks and abortive medications to relieve strong and periodic pain.

The growth of the global migraine drugs market is driven by various factors such as an increasing global geriatric population, rising prevalence of migraine, growing awareness about migraine in developing economies, rising R&D investment for the development of innovative drugs for the treatment of migraine, and increasing demand for better treatment methods for migraine. However, stringent government regulations, high investment required for drug research & development, and side-effects of medications prescribed for migraine are the factors that are expected to limit the growth of the global migraine drugs market during the forecast period.

The global migraine drugs market is currently dominated by several market players. The key players are involved in product launches and strategic collaborations to strengthen their market positions. Migraine treatment drugs available are approved for the acute form of the condition, led by generic triptans as the first-line treatment. The global migraine treatment market is witnessing a rapid shift in terms of strong R&D with the launch of CGRP-based therapies and approval of novel drug classes such as ditans, gepants, and reformulation of triptans for the treatment of both chronic and episodic migraine. Launch of late-stage pipeline products such as erenumab, galcanezumab, fremanezumab, and eptinezumab by major players such as Eli Lilly and Company, Alder Pharmaceuticals, Inc., Teva Pharmaceuticals Ltd, and Amgen strengthened its market position in the global migraine drugs market in 2018.

Request Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/8379

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas is expected to be the largest market owing to the increasing prevalence of migraine and R&D by major players in the region. For instance, in September 2018, Eli Lilly and Company launched Emgality (galcanezumab-gnlm) injection (300 mg) for the preventive treatment of migraine in adults. It is the first drug to receive Food and Drug Administration (FDA) approval for decreasing the frequency of episodic cluster headache attacks. The migraine drugs market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada.

The European migraine drugs market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The migraine drugs market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Growing geriatric population, increasing patients suffering from neurological diseases, raising awareness about migraine, government initiatives in emerging economies to provide better healthcare infrastructure, and strategic initiatives by regional and market leaders are driving the migraine market in Asia-Pacific. The Asia-Pacific region is expected to be the fastest-growing during the forecast period.

The migraine drugs market in the Middle East & Africa has been divided into the Middle East and Africa.

Segmentation

The global migraine drugs market has been segmented based on type, treatment, drug class, and end user.

The global migraine drugs market has been segmented, on the basis of migraine-type into episodic migraine and chronic migraine.

The global migraine drugs market has been segmented, on the basis of treatment type, into, acute, preventive, neuromodulation, and others.

The acute segment is expected to hold the majority share of the market as the prevalence of acute migraine is high, and most of the drugs manufactured by major companies are for the treatment of acute migraine.

The global migraine drugs market has been segmented, on the basis of drug class, into beta-blockers, Angiotensin Blockers, tricyclics, anticonvulsants, triptans, and others.

Triptons are the most preferred type of drugs class for migraine patients due to its high efficacy. It holds the major share in the market by drug class. Approximately 80% of the migraine patients are treated with Triptans, and more than 40% of the patients suffering from cardiovascular diseases with migraine were treated with triptans in 2018.

The market on the basis of end user has been segmented into hospitals and clinics, research and academic institutes, and others. The hospitals and clinics segment is expected to hold the largest share of the market as they are primary centers of treatment for the patient. The retail pharmacy segment offers over the counter (OTC) and prescription migraine drugs though a chain of pharmacies globally. Other end users include online pharmacy segment that offers OTC migraine drugs through e-commerce platforms.

Key Players

Some of the key players in the global migraine drugs market are Allergan Plc (Ireland), Alder Biopharmaceuticals, Inc. (US), Pfizer Inc. (US), GlaxoSmithKline Plc (UK), Merck & Co., Inc. (US), Teva Pharmaceutical Industries Ltd (Israel), AstraZeneca Plc (UK), Johnson & Johnson Services, Inc. (US), Amgen Inc (US), Eli Lilly and Company, and eNeura Inc.

Table Of Contents

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope Of The Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power Of Suppliers

5.1.2. Bargaining Power Of Buyers

5.1.3. Threat Of New Entrants

5.1.4. Threat Of Substitutes

5.1.5. Intensity Of Rivalry

5.2. Value Chain Analysis

Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/migraine-drugs-market-8379

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Related Report:

Opioids Market Research Report - Forecast to 2023

Contact:

Akash Anand

Market Research Future

+1 646 845 9312

Email: [email protected]

#global migraine drugs market

0 notes

marketresearchstrategy · 3 years ago

Text

In vivo CRO Industry Supply Chain Analysis, Growth Opportunities, Top Companies, Revenue Growth and Business Development Report by 2027

The global in vivo CRO market size reached USD 3.61 Billion in 2020 and is expected to reach USD 6.44 Billion in 2028 and register a CAGR of 8.6% over the forecast period, according to latest analysis by Reports and Data. The in vivo CRO market revenue growth is fueled by various factors including increasing demand for the CROs (Contract Research Organization) in pharmaceutical drug development, rising price competition among companies, and growing requirement to reduce cost combined with rising demand for advanced products. Additionally, changing regulatory policies in several organizations, and increasing chronic medical conditions are some of the factors also expected to contribute to the revenue growth of the global in vivo CRO market during the forecast period. Furthermore, the in vivo CRO market revenue growth is increasing at a significant extent, as drug manufacturers increases their pipeline products in order to develop as well as manufacture new molecule to sustain in the market with good profit, and with a patent product.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/1634

The report initially offers market introduction, market overview, product scope, market opportunities, growth prospects, risks, limitations, and key drivers. The report also covers a comprehensive analysis of the competitive landscape with extensive profiling of the key competitors. It covers recent technological advancements, product developments, product launches, mergers and acquisitions, collaborations, joint ventures, and partnerships.

Key Companies in the market include:

American Preclinical Services, LLC, BTS Research, Charles River Laboratories, Chiltern International Ltd., Crown Bioscience, Eurofins Scientific, Evotec, ICON PLC, INC Research, inVentiv Health, Parexel International, Pharmaceutical Product Development, LLC (PPD), PRA Health Sciences, Quintiles, Taconic Biosciences and Theorem Clinical Re

Regional segmentation comprises of a current and forecast estimation of the market in the key geographical regions such as North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The report also covers the scope of individual applications and types in each region. The report also covers details about production and consumption patterns, technological developments, revenue growth, market size, market share, key trends and demands influencing market growth in the region, and robust presence of key players in the region.

Market segment analysis:

Type Outlook (Revenue: USD Billion; 2017-2027)

Rats

Mice

Others

Hamsters

Guinea Pigs

Others

GLP Type Outlook (Revenue: USD Billion; 2017-2027)

In House

Outsourcing

In House

Outsourcing

Indication Outlook (Revenue: USD Billion; 2017-2027)

Rheumatoid Arthritis

Multiple Sclerosis

Osteoarthritis

Irritable Bowel Syndrome

Others

Chronic Pain

Acute Pain

Blood Cancer

Solid Tumor

Syngeneic Model

Patient Derived Xenograft

Xenograft

Others

Epilepsy

Parkinson’s Disease

Huntington’s Disease

Stroke

Traumatic Brain Injury

ALS

Muscle Regeneration

Others

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/1634

Regional analysis further covers a country-wise analysis to offer insights into key trends and demands in each major country that might affect the growth of the market in the region.

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

U.S.

Canada

Mexico

Germany

U.K.

Italy

France

BENELUX

Rest of Europe

China

India

Japan

South Korea

Rest of APAC

Brazil

Rest of LATAM

Saudi Arabia

A.E.

South Africa

Rest of MEA

To know more about the report @ https://www.reportsanddata.com/report-detail/in-vivo-cro-market

Key Features of the Global In vivo CRO Market Report:

Comprehensive analysis of the key players operating in the market along with their SWOT analysis, their business profiles, business overview, market share, global position, and market value

Identification and analysis of significant trends and factors driving revenue growth of the market

Analysis of the competitive landscape along with strategic mergers, expansions, agreements, partnerships, joint ventures, acquisitions, and product launches

Assessment of each market segment along with their growth trends and market revenue contribution

Study of the key regions to pinpoint growth potential and study opportunities, threats, limitations, and risks

Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/1634

Thank you for reading our report. Customization of this report is available according to the client’s needs. Please get in touch with us to know more about the customization feature and our team will ensure the report is tailored as per your requirements.

Browse more reports:

Hot Melt Adhesives Market Size

Off Highway Vehicle Engine Market Share

0 notes

researchreportinsight · 4 years ago

Text

Nitrous Oxide Market Size, Sales, Demand, Regional Outlook And Supply Chain Analysis till 2025

19th May 2021 – The global nitrous oxide market witnessed market value of USD 805.1 million in 2016 owing to rise in demand from several industries such as electronics, automotive, food & beverages and medical. Nitrous oxide is used as an efficiency enhancer and further injected to boost gas engines. In addition, nitrous oxide is also used in dental treatments for analgesic purpose. However, stringent government regulations coupled with strict norms by food & drug administration arelikely to restrict the market growth in the near future. Overall, the nitrous oxide market is anticipated to register a CAGR of 7.1% in the near future.

Nitrous oxide is produced commercially by heating ammonium nitrate to a higher temperature. A channel with washers and scrubbers subsequently eliminate water vapor with high oxides of ammonia, nitrogen and nitric acid, and the other impurities. Nitrous oxide is normally stored below its acute temperature and exists in liquid and vapor phases. Unlike cylinders comprising pressurized gas, the cylinder pressure remains constant until all the liquid nitrous oxide vaporizes. A minor change in pressure might occur during the emission of nitrous oxide and ice may form on the exterior of cylinders due to constant cooling upon nitrous oxides latent heat vaporization. A pipeline is enabled for supply of nitrous oxide and achieved via a large central repository of cylinders comprising reserve storage. In clinical application, nitrous oxide is used as general anesthesia, for obstetrics, and pain management. Therefore, on a commercial scale nitrous oxide has played a pivotal role in anesthesia. At present, no alternative exists for using nitrous oxide for clinical and medical applications.

Geographical segmentation for nitrous oxide industry spans North America, South America, Europe, Asia-Pacific and MiddleEast & Africa. Furthermore, rise in demand from Asia-Pacific’s market is expected to boost the global market scenario. Asia-Pacific’s market witnesses rise in geriatric population, due to existence of prolonged chronic disease in emerging economies such as India and China. North American market is expected to lead the market share in the forecast period since it offers multiple growth opportunities and untapped potential in the global market. Middle Eastern and African market is likely to enjoy lucrative share in growth owing to presence of oil and manufacturing companies.

The key players in the nitrous oxide market include Praxair Technology, Inc.; Oxygen & Argon Works Ltd.; The Linde Group; Matheson Tri-Gas, Inc.; SOL Spa; Merck KGaA; Air Liquide; Airgas, Inc.; and Ellenbarrie Industrial Gases Ltd., Promas Engineers Pvt. Ltd., SS Gas Lab Asia, and KVK Corporation.

Request a Sample Copy of Nitrous Oxide Market Report @ https://www.millioninsights.com/industry-reports/nitrous-oxide-market/request-sample

0 notes

chitrakullkarni · 4 years ago

Text

Nitrous Oxide Market Segmentation By Top Trends, Manufacturers, and Region, 2025

The global Nitrous Oxide Market research report provides complete insights on industry scope, trends, regional estimates, key application, competitive landscape and financial performance of prominent players. It also offers ready data-driven answers to several industry-level questions. This study enables numerous opportunities for the market players to invest in research and development.

Market Overview:

The global nitrous oxide market witnessed market value of USD 805.1 million in 2016 owing to rise in demand from several industries such as electronics, automotive, food & beverages and medical. Nitrous oxide is used as an efficiency enhancer and further injected to boost gas engines. In addition, nitrous oxide is also used in dental treatments for analgesic purpose.

Key Players:

Oxygen and Argon Works Ltd.

Praxair

The Linde Group

Airgas

Matheson Tri-Gas Inc.

SOL S.p.A.

Merck KGaA

Air Liquide S.A.

Ellenbarrie Industrial Gases Ltd.

Promas Engineers Pvt. Ltd.

SS Gas Lab Asia

Request free sample to get a complete analysis of top-performing companies @ https://www.millioninsights.com/industry-reports/nitrous-oxide-market/request-sample

Growth Drivers:

Nitrous oxide is also used in dental treatments for analgesic purpose. However, stringent government regulations coupled with strict norms by food & drug administration arelikely to restrict the market growth in the near future. Overall, the nitrous oxide market is anticipated to register a CAGR of 7.1% in the near future.

Nitrous oxide is produced commercially by heating ammonium nitrate to a higher temperature. A channel with washers and scrubbers subsequently eliminate water vapor with high oxides of ammonia, nitrogen and nitric acid, and the other impurities. Nitrous oxide is normally stored below its acute temperature and exists in liquid and vapor phases. Unlike cylinders comprising pressurized gas, the cylinder pressure remains constant until all the liquid nitrous oxide vaporizes.

A minor change in pressure might occur during the emission of nitrous oxide and ice may form on the exterior of cylinders due to constant cooling upon nitrous oxide’s latent heat vaporization. A pipeline is enabled for supply of nitrous oxide and achieved via a large central repository of cylinders comprising reserve storage. In clinical application, nitrous oxide is used as general anesthesia, for obstetrics, and pain management. Therefore, on a commercial scale nitrous oxide has played a pivotal role in anesthesia. At present, no alternative exists for using nitrous oxide for clinical and medical applications.

Application Outlook:

Automotive

Medical

Electronics

Food & Beverages

Regional Outlook:

Geographical segmentation for nitrous oxide industry spans North America, South America, Europe, Asia-Pacific and MiddleEast & Africa. Furthermore, rise in demand from Asia-Pacific’s market is expected to boost the global market scenario. Asia-Pacific’s market witnesses rise in geriatric population, due to existence of prolonged chronic disease in emerging economies such as India and China.

North American market is expected to lead the market share in the forecast period since it offers multiple growth opportunities and untapped potential in the global market. Middle Eastern and African market is likely to enjoy lucrative share in growth owing to presence of oil and manufacturing companies.

Browse Related Category Research Reports @ https://blog.naver.com/tomclark

0 notes

priyacmi · 4 years ago

Text

DIABETIC GASTROPARESIS TREATMENT MARKET ANALYSIS

Diabetic gastroparesis is delayed gastric emptying associated with diabetes. The condition occurs in patients suffering from both type-1 and type- 2 diabetes and is more common in female patients suffering from type-2 diabetes. The disease involves delayed emptying of the stomach leading to a series of symptoms such as nausea, vomiting, abdominal bloating, abdominal pain, weight loss, gastroesophageal reflux, spasms of the stomach wall, and heartburn.

The global diabetic gastroparesis treatment market is estimated to account for US$ 3,069.8 Mn in terms of value in 2018 and is expected to reach US$ 4,252.2 Mn by the end of 2027.

Global Diabetic Gastroparesis Treatment Market: Drivers

Increasing prevalence of diabetes is expected to propel growth of the global diabetic gastroparesis treatment market over the forecast period. For instance, according to the study, ‘Global Prevalence of Type 2 Diabetes over the Next Ten Years (2018-2028)’, published by the American Diabetes Association, 500 million people worldwide suffered from type 2 diabetes in 2018.

Moreover, easy access to off-label medicines without prescriptions is expected to boost growth of the market. Medications such as anti-emetic drugs (oandesteron) are affordable and easily accessible in emerging economies. Moreover, increasing inclination towards OTC medicines to avoid higher expenses is also leading to greater disbursement of drugs through retail pharmacies and drugstores.

North America region held dominant position in the global diabetic gastroparesis treatment market in 2018, accounting for 38.5% share in terms of value, followed by Europe.

Global Diabetic Gastroparesis Treatment Market: Restraints

Lack of clinical evidence on improvement offered by prescription drugs is expected to hinder growth of the global diabetic gastroparesis treatment market. There is very little documented clinical evidence provided for prescription drugs for the treatment of diabetic gastroparesis. Metoclopramide, domperidon, and erythromycin are used for the treatment of diabetic gastroparesis. However, approvals of these drugs are inconsistent across countries, leading to lack of availability of consistent patient improvement data due to administration of these drugs. In emerging economies, the disease remains largely untreated or often treated through non-prescription OTC drugs, which again is responsible for dearth of clinical evidence regarding improvement in quality of life for patients after consuming these drugs for the treatment of diabetic gastroparesis.

Moreover, withdrawal/termination of clinical trials is also expected to hamper growth of the market. There are very few drugs in the pipeline, which have the potential for the treatment of diabetic gastroparesis. This is due to early termination of clinical trials or failure of drugs to meet statistically significant endpoints. For instance, in August 2018, Dartmouth-Hitchcock Medical Center terminated the randomized, double-blind, placebo-controlled trial of promethazine for treatment of diabetic gastroparesis, conducted in collaboration with American College of Gastroenterology, due to lack of recruitment.

Global Diabetic Gastroparesis Treatment Market: Opportunities

Measures to support product approval and labeling claims for diabetic gastroparesis treatments is expected to offer lucrative growth opportunities for players in the global diabetic gastroparesis treatment market. For instance, in February 2019, a team of researchers affiliated with Boston Therapeutics, Inc. reported that The Diabetic Gastroparesis Symptom Severity Diary can be a reliable and valid measure that can be used to derive endpoints to evaluate treatment benefit in future diabetic gastroparesis interventional trials.

Moreover, initiatives of regulatory bodies to issue guidance for development of drugs for the treatment of diabetic gastroparesis is also expected to aid in growth of the market. For instance, in August 2019, the U.S. FDA issued guidance that addresses FDA’s current recommendations regarding clinical trial designs and clinical endpoint assessments to support the development of drugs for the treatment of idiopathic and diabetic gastroparesis.

Drugs segment in the global diabetic gastroparesis treatment market was valued at US$ 1,924.5 Mn in 2018 and is expected to reach US$ 2,646.8 Mn by 2027 at a CAGR of 3.6% during the forecast period.

Market Trends/Key Takeaways

The market is witnessing R&D in non-invasive approaches for the treatment of diabetic gastroparesis. For instance, a pilot study presented at the 2019 annual meeting of the North American Neuromodulation Society assessed the effectiveness of the gammaCore hand-held vagal nerve stimulator for the treatment of gastroparesis.

Gastric Per-Oral Endoscopic Pyloromyotomy (GPOEM) is a safe and effective therapy for refractory gastroparesis. For instance, researchers from Emory University (U.S) assessed the safety and efficacy of GPOEM and compared clinical outcomes between diabetic and non-diabetic cohorts and found that patients with predominant nausea/vomiting and short duration of diabetic gastroparesis may opt for GPOEM.

Regulations

U.S.

ICD-10-CM

Reimbursement claims with a date of service on or after Oct 1, 2015 require the use of ICD-10-CM codes

This is the American ICD-10-CM version of K31.84. Other international ICD-10 versions may differ

61 (diabetes with neurological manifestations)

3 (gastroparesis)

43 (Type 1 diabetes mellitus with diabetic autonomic [poly]neuropathy)

ICD-9-CM

Diabetes type 1 with gastroparesis

Diabetes type 2 with gastroparesis

Diabetic gastroparesis

Diabetic gastroparesis associated with type 1 diabetes mellitus

diabetic gastroparesis associated with type 2 diabetes mellitus

DM 1 w diabetic gastroparesis

DM 2 W diabetic gastroparesis

Gastroparesis due to diabetes

Gastroparesis due to DM

Gastroparesis syndrome

3 is a billable medical code that can be used to indicate a diagnosis on a reimbursement claim

gastrica 536.8

neurogenic 536.3

psychogenic 306.4

dyspepsia 536.3

psychogenic 306.4

stomach 536.3

neurotic or psychogenic 306.4

psychogenic 306.4

Diabetic gastroparesis drugs are eligible for reimbursement in in-patient hospitalization cases, when there a proven medical necessity

Diabetic gastroparesis treatment devices are medically necessary as these are used in severe cases of refractory gastroparesis. These are eligible for reimbursement from both public and private payers in the U.S.

Global Diabetic Gastroparesis Treatment Market: Key Developments

Major players operating in the global diabetic gastroparesis treatment market include, Janssen Global Services, LLC, Cardinal Health, Inc., Evoke Pharma, Inc., Salix Pharmaceuticals, Inc., Alfa Wassermann SPA, Abbott Laboratories, Medtronic Plc., C. R. Bard, Inc. (Becton, Dickinson and Company), Rhythm Pharmaceuticals, Inc., Boston Scientific Corporation, Kimberly-Clark Corporation, Vanda Pharmaceuticals, Inc., and Allergan, plc.

https://www.coherentmarketinsights.com/insight/request-sample/3603

https://www.coherentmarketinsights.com/insight/request-pdf/3603

Global Diabetic Gastroparesis Treatment Market: Key Developments

Major players in the market are focused on approval and launch of new products to expand their product portfolio. For instance, in January 2020, Evoke Pharma, Inc., a developer of drugs for the treatment of gastrointestinal disorders and diseases, announced that the U.S. FDA accepted the company’s resubmission of its 505(b)(2) New Drug Application (NDA) for Gimoti, a nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis.

Major players in the market are also focused on conducting clinical trials to expand their product portfolio. For instance, in December 2018, Vanda Pharmaceuticals, Inc. announced that tradipitant met the primary endpoint in a Phase II clinical study in patients with idiopathic and diabetic gastroparesis.

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

What we provide:

Customized Market Research Services

Industry Analysis Services

Business Consulting Services

Market Intelligence Services

Long term Engagement Model

Country Specific Analysis

Contact Us:

Mr. Shah

Coherent Market Insights Pvt. Ltd.

Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.

Phone: +1-206-701-6702

Email: [email protected]

Source: https://www.coherentmarketinsights.com/market-insight/diabetic-gastroparesis-treatment-market-3603

0 notes

kritikarehani · 4 years ago

Text

Pyelonephritis Market Size, Share, Trends, Research Report 2030

Pyelonephritis (Kidney infection) is an infection of the kidney that most often occurs when a urinary tract infection spreads beyond the bladder to the ureters and kidneys.

DelveInsight's "Pyelonephritis - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Pyelonephritis, historical and forecasted epidemiology as well as the Pyelonephritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Pyelonephritis market report provides current treatment practices, emerging drugs, Pyelonephritis market share of the individual therapies, current and forecasted Pyelonephritis market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Pyelonephritis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

· The United States

· EU5 (Germany, France, Italy, Spain, and the United Kingdom)

· Japan

Study Period: 2017-2030

View full report: https://www.delveinsight.com/report-store/pyelonephritis-market

Pyelonephritis Disease Understanding and Treatment Algorithm

The most common cause of the disease is bacterial infection and based on the severity it is classified into acute and chronic pyelonephritis. The main cause of acute pyelonephritis is gram-negative bacteria, the most common being Escherichia coli. Other gram-negative bacteria which cause acute pyelonephritis include Proteus, Klebsiella, and Enterobacter. Acute pyelonephritis can be further subdivided into uncomplicated and complicated pyelonephritis.

Reflux-associated chronic pyelonephritis is the most common form and occurs when there is a reflux of urine from the bladder resulting in kidney scarring. Obstructive chronic pyelonephritis occurs from recurrent episodes of kidney infection that result from distal obstruction.

The common symptoms of pyelonephritis are fever, chills, cloudy dark bloody or foul-smelling urine, frequent and painful urination, nausea, and vomiting.

The DelveInsight Pyelonephritis market report gives a thorough understanding of the Pyelonephritis by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Pyelonephritis.

Treatment

It covers the details of conventional and current medical therapies available in the Pyelonephritis market for the treatment of the condition. It also provides Pyelonephritis treatment algorithms and guidelines in the United States, Europe, and Japan.

Request for sample pages: https://www.delveinsight.com/sample-request/pyelonephritis-market

Pyelonephritis Epidemiology

The Pyelonephritis epidemiology division provide insights about historical and current Pyelonephritis patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

A population-based study of acute pyelonephritis (APN) in the United States found overall annual rates of 15–17 cases per 10,000 females and 3–4 cases per 10,000 males (Czaja, Scholes, Hooton, & Stamm, 2007).

Approximately 20–35% of females experience an episode of APN in their lifetime (Clementi, 2015).

An estimated one in 830 people in the UK experience pyelonephritis every year, and females are six times more likely to experience the infection than males.

The disease epidemiology covered in the report provides historical as well as forecasted Pyelonephritis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Pyelonephritis Epidemiology

The epidemiology segment also provides the Pyelonephritis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

View Epidemiology Insights of the report: https://www.delveinsight.com/report-store/pyelonephritis-epidemiology-forecast

Pyelonephritis Drug Chapters

Key players, such as Spero Therapeutics, Allecra Therapeutics, VenatoRx Pharmaceuticals, Nabriva Therapeutics, etc., are involved in developing therapies for the treatment of Pyelonephritis. Contepo (Nabriva Therapeutics), Tebipenem HBr (SPR994) (Spero Therapeutics), Cefepime-Enmetazobactam/AAI101 (Allecra Therapeutics), Cefepime/taniborbactam (VenatoRx Pharmaceuticals) and along with other compelling treatment options in the clinical trials is expected to increase the overall market size of pyelonephritis.

Drug chapter segment of the Pyelonephritis report encloses the detailed analysis of Pyelonephritis marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Pyelonephritis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Pyelonephritis treatment.

Pyelonephritis Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Pyelonephritis treatment.

Click here to see pipeline insights of the report: https://www.delveinsight.com/report-store/pyelonephritis-pipeline-insight

Pyelonephritis Market Outlook

Pyelonephritis is a type of urinary tract infection that commonly begins in the bladder and moves upstream to one or both of the kidneys. In rare cases, kidney infections can lead to serious health problems, but quick treatment prevents most complications.

The Pyelonephritis market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Pyelonephritis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Pyelonephritis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Pyelonephritis market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Pyelonephritis market in 7MM.

The United States Market Outlook

This section provides the total Pyelonephritis market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Pyelonephritis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Pyelonephritis market size and market size by therapies in Japan is also mentioned.

Download market insights of the report: https://www.delveinsight.com/sample-request/pyelonephritis-market

#Pyelonephritis Market share #Pyelonephritis Market size #Pyelonephritis Market trends #Pyelonephritis Market research reports #Pyelonephritis Market market scenario #Pyelonephritis Market outlook

0 notes

clevertimetravelpaper · 2 years ago

Text

Anti-Inflammatory Therapeutics Market by Size, Demand, Development, Opportunity, Growth, Trends, Business, Industry, Dynamic, Market Value and Forecast to 2027

Global anti-inflammatory therapeutics market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing with the healthy CAGR in the above-mentioned research forecast period. Emerging markets and huge investment in research and development are the factors responsible for the growth of this market.

The growth of anti-inflammatory therapeutics market is anticipated by the high prevalence of chronic disorders such as arthritis and psoriasis and rise in focuses on the anti-inflammatory therapeutics. In addition, increase patient awareness level, availability of the treatment options and adoption of sedentary life-style are some of the influencing factors for the growth of anti-inflammatory therapeutics market. The market for anti-inflammatory therapeutics is majorly hampered by limited revenue opportunities with multiple patent expiries of branded drugs. Anti-inflammatory drugs are therapeutics which is widely used to reduce acute as well as mild chronic pain associated with the chronic disorders. It is available as over-the counter and prescription drugs. Basically, these drugs inhibit the production of certain body chemicals that cause inflammation.

Get a Sample PDF of the report –https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-anti-inflammatory-therapeutics-market